Autoimmune Disease News and Research

RSS

Autoimmune Disease is a condition in which the body recognizes its own tissues as foreign and directs an immune response against them.

Australia's top medical researchers for 2012 announced

Finalists for one of Australia’s longest running and most prestigious awards for medical research were announced today. This year’s winner will join a list of alumni winners that includes many of the country’s most respected scientists.

31 Jul 2012

Top-line results from Pfizer's tofacitinib Phase 3 study on moderate-to-severe active RA

Pfizer Inc. announced today top-line results from ORAL Start (A3921069), a Phase 3 study of the investigational agent tofacitinib, a novel, oral Janus kinase (JAK) inhibitor for the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA).

31 Jul 2012

Genentech's BREVACTA study of ACTEMRA on rheumatoid arthritis meets primary endpoint

Genentech, a member of the Roche Group, today announced that the BREVACTA study of ACTEMRA (tocilizumab) given as a subcutaneous (SC) injection to patients with rheumatoid arthritis (RA) met its primary endpoint.

28 Jul 2012

EMA COMP issues positive opinion to Albireo for A4250

Albireo AB, a biopharmaceutical company specializing in gastroenterology, today announced that the European Medicines Agency Committee for Orphan Medicinal Products (COMP) has issued a positive opinion on an application for orphan medicinal product status for the company's lead hepatology candidate, A4250.

25 Jul 2012

Anti-IL-3 monoclonal antibodies to treat early stage Rheumatoid Arthritis in development

SuppreMol GmbH, an autoimmune disease specialist, today announced a licensing agreement with the University Hospital of Regensburg to develop SM401, a humanized anti-IL-3 monoclonal antibody for early diagnosis and treatment of Rheumatoid Arthritis (RA). SuppreMol will advance preclinical development of SM401 for treatment of RA. Simultaneously, the Company will further validate a highly sensitive human IL-3 diagnostic assay for patient stratification.

24 Jul 2012

Anthera announces final set of clinical data from blisibimod Phase 2b study on SLE

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced the final set of clinical data from the Phase 2b PEARL-SC study in patients with systemic lupus erythematosus.

17 Jul 2012

Stress management treatment reduces formation of new brain lesions in people with MS

Research conducted by Jesus Lovera, MD, Assistant Professor of Neurology at LSU Health Sciences Center New Orleans, and colleagues has shown that stress management treatment significantly reduced the formation of new brain lesions in people with multiple sclerosis (MS) over the course of treatment.

17 Jul 2012

Rheumatoid arthritis risk reduced by moderate alcohol consumption

Moderate consumption of alcohol is associated with a reduced risk of developing rheumatoid arthritis, suggests a study published on bmj.com today.

11 Jul 2012

RA patients do not receive fewer cancer screening tests than general population: Study

New research reveals that rheumatoid arthritis (RA) patients do not receive fewer cancer screening tests than the general population. Results of the study, funded in part by grants from the National Institutes of Health (NIH) and published in Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR), found that RA and non-RA patients receive routine screening for breast, cervical, and colon cancer at similar rates.

10 Jul 2012

Human immune response: TCD scientists make breakthrough which could lead to new drug therapies

A team of researchers at Trinity College Dublin’s School of Medicine has gained new insights into a protein in the human immune system that plays a key role in the protective response to infection and inflammation. The research findings have just been published in the internationally renowned peer-reviewed Journal of Biological Chemistry.

9 Jul 2012

Scientists use antibody injections to rapidly reverse onset of Type I diabetes in mice

Scientists at the University of North Carolina School of Medicine have used injections of antibodies to rapidly reverse the onset of Type I diabetes in mice genetically bred to develop the disease. Moreover, just two injections maintained disease remission indefinitely without harming the immune system.

6 Jul 2012

Study illuminates key step in the journey of inflammation-producing immune cells

Like detectives seeking footprints and other clues on a television "whodunit," science can also benefit from analyzing the tracks of important players in the body's molecular landscape. Klaus Ley, M.D., a scientist at the La Jolla Institute for Allergy & Immunology, has done just that and illuminated a key step in the journey of inflammation-producing immune cells.

2 Jul 2012

Novo Nordisk, BRI collaborate to speed-up translational research of autoimmune diseases

Benaroya Research Institute at Virginia Mason (BRI), a non-profit biomedical research institute in Seattle, Wash., and Novo Nordisk, a global health care company headquartered in Denmark, today announced a three-year collaborative agreement to potentially speed-up translational research of the diagnosis and treatment of rheumatoid arthritis, inflammatory bowel disease and lupus.

29 Jun 2012

DFG to set up new CRC/Transregio that focuses on multiple sclerosis research

On July 1, 2012, the German Research Foundation (DFG) will set up a new Transregional Collaborative Research Center (CRC/Transregio) to be coordinated by the University Medical Center of Johannes Gutenberg University Mainz.

29 Jun 2012

Dietary fiber can improve gastrointestinal health

A University of Illinois study shows that dietary fiber promotes a shift in the gut toward different types of beneficial bacteria. And the microbes that live in the gut, scientists now believe, can support a healthy gastrointestinal tract as well as affect our susceptibility to conditions as varied as type 2 diabetes, obesity, inflammatory bowel disease, colon cancer, and autoimmune disorders such as rheumatoid arthritis.

28 Jun 2012

Anthera announces results from blisibimod Phase 2b study on SLE

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced results from the Phase 2b PEARL-SC clinical study in patients with systemic lupus erythematosus.

28 Jun 2012

AARDA to host forum related to autoimmune diseases on Aug. 4

The American Autoimmune Related Diseases Association (AARDA) is hosting a "What Every American Needs to Know About Autoimmune Disease" forum on Saturday, August 4th , 2012.

27 Jun 2012

Scientists recommend new type of therapeutic approach to dementia

Scientists at Charité - Universitätsmedizin Berlin have succeeded in recommending a new type of therapeutic approach to dementia. The study published in the journal Neurology shows that immune reactions against the body's own nerve cells can be the cause of advanced dementia and an appropriate immune suppressive therapy can develop with significant effectiveness.

23 Jun 2012

First study to demonstrate that microbes are specific to their host species

Gut bacteria's key role in immunity is tuned to the host species, researchers have found, suggesting that the superabundant microbes lining our digestive tract evolved with us-a tantalizing clue in the mysterious recent spike in human autoimmune disorders.